PhysQuiz Answers! SABCS 2020
1) In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer ADC trastuzumab deruxtecan (Enhertu) continued to demonstrate favorable data, including a median progression-free...
Read More